A first Czech analysis of 1887 cases with monoclonal gammopathy of undetermined significance
Language English Country Great Britain, England Media print-electronic
Document type Journal Article
PubMed
28384387
DOI
10.1111/ejh.12894
Knihovny.cz E-resources
- Keywords
- monoclonal gammopathy, multiple myeloma, progression, risk factors,
- MeSH
- Biomarkers MeSH
- Risk Assessment MeSH
- In Situ Hybridization, Fluorescence MeSH
- Kaplan-Meier Estimate MeSH
- Bone Marrow pathology MeSH
- Middle Aged MeSH
- Humans MeSH
- Monoclonal Gammopathy of Undetermined Significance diagnosis epidemiology metabolism MeSH
- Myeloma Proteins metabolism MeSH
- Cell Transformation, Neoplastic MeSH
- Plasma Cells metabolism pathology MeSH
- Disease Progression MeSH
- Proportional Hazards Models MeSH
- Registries MeSH
- Risk Factors MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Population Surveillance MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Geographicals
- Czech Republic epidemiology MeSH
- Names of Substances
- Biomarkers MeSH
- multiple myeloma M-proteins MeSH Browser
- Myeloma Proteins MeSH
INTRODUCTION: Monoclonal gammopathy of undetermined significance (MGUS) is a premalignant condition with a risk of malignant conversion. PATIENTS AND METHODS: With the aim to estimate the cumulative risk MGUS progression to hematologic malignancies, we analyzed a nationwide population-based cohort of 1887 MGUS patients from the Czech Registry of Monoclonal Gammopathies (RMG) between 2007 and 2013. RESULTS: During the follow-up period (median 4 years; range 0.6-34.8), progression to hematologic malignancies was observed in 8.6% (162 of 1887) of patients. Factors associated with progression were as follows: M-protein concentration ≥1.5 g/dL, pathological sFLC (<0.26 or >1.65) ratio, bone marrow plasma cells (BMPCs) in cytology >5%, immunoparesis, age ≥69 years, and the level of serum hemoglobin at baseline <12.0 g/dL. Combining these factors, we propose a new risk model (CMG model). The risk of progression at 10 years was 1.6%, 16.9%, 22.9%, 39.4%, and 52.3%, respectively, if 0 (reference group), one, two, three, or four to five risk factors are present (P<.001) with HR 63 times higher compared to the reference MGUS group. CONCLUSION: The new CMG model was established with an advantage for better identification of MGUS patients at low risk.
Department of Clinical Hematology Hospital České Budejovice Czech Republic
Department of Clinical Hematology Hospital Havířov Czech Republic
Department of Clinical Hematology Hospital Liberec Czech Republic
Department of Clinical Hematology Hospital Nový Jičín Czech Republic
Department of Clinical Hematology Thomayer Hospital Praha Czech Republic
Department of Clinical Hematology University Hospital Brno Brno Czech Republic
Department of Clinical Hematology University Hospital Kralovske Vinohrady Praha Czech Republic
Department of Clinical Hematology University Hospital Ostrava Czech Republic
Department of Experimental Biology Faculty of Science Masaryk University Brno Czech Republic
Department of Hemato Oncology University Hospital Olomouc Czech Republic
Department of Hematology and Transfusion Hospital Mlada Boleslav Czech Republic
Department of Hematology and Transfusion Hospital Opava Czech Republic
Department of Hematology and Transfusion Medicine Hospital Pelhřimov Czech Republic
Department of Internal Medicine Hematology and Oncology University Hospital Brno Czech Republic
Department of Internal Medicine University Hospital Praha Czech Republic
Department of Medicine Hematology University Hospital Hradec Kralove Czech Republic
Institute of Biostatistics and Analyses Faculty of Medicine Masaryk University Brno Czech Republic
References provided by Crossref.org
